Volume 73, Issue 10 p. 1878-1885
Full Length

The Epidemiology of Psoriatic Arthritis Over Five Decades: A Population-Based Study

Paras Karmacharya

Corresponding Author

Paras Karmacharya

Mayo Clinic, Rochester, Minnesota

Address correspondence to Paras Karmacharya, MBBS, MS, Mayo Clinic College of Medicine, Division of Rheumatology, 200 First Street Southwest, Rochester, MN 55905. Email: [email protected].

Search for more papers by this author
Cynthia S. Crowson

Cynthia S. Crowson

Mayo Clinic, Rochester, Minnesota

Search for more papers by this author
Delamo Bekele

Delamo Bekele

Mayo Clinic, Rochester, Minnesota

Search for more papers by this author
Sara J. Achenbach

Sara J. Achenbach

Mayo Clinic, Rochester, Minnesota

Search for more papers by this author
John M. Davis III

John M. Davis III

Mayo Clinic, Rochester, Minnesota

Search for more papers by this author
Alexis Ogdie

Alexis Ogdie

University of Pennsylvania Perelman School of Medicine, Philadelphia

Search for more papers by this author
Alí Duarte-García

Alí Duarte-García

Mayo Clinic, Rochester, Minnesota

Search for more papers by this author
Floranne C. Ernste

Floranne C. Ernste

Mayo Clinic, Rochester, Minnesota

Search for more papers by this author
Hilal Maradit-Kremers

Hilal Maradit-Kremers

Mayo Clinic, Rochester, Minnesota

Search for more papers by this author
Megha M. Tollefson

Megha M. Tollefson

Mayo Clinic, Rochester, Minnesota

Search for more papers by this author
Kerry Wright

Kerry Wright

Mayo Clinic, Rochester, Minnesota

Search for more papers by this author
First published: 28 March 2021
Citations: 15
The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Supported by the Rochester Epidemiology Project of the National Institute on Aging, NIH (grant R01-AG-034676) and by the National Center for Advancing Translational Sciences, NIH (grant UL1-TR-002377). Dr. Karmacharya’s work was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH (grant T32-AR-56950 for the Musculoskeletal Research Training Program) and by a pilot research grant from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Dr. Duarte-García’s work was supported by the CDC, a Rheumatology Research Foundation Scientist Development award, the Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, a Women's Health Career Enhancement award, and an Eaton Family Career Development award.
Dr. Davis has received consulting fees, speaking fees, and/or honoraria from AbbVie and Sanofi-Genzyme (less than $10,000 each) and research support from Pfizer. Dr. Ogdie has received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB (less than $10,000 each) and research grants paid to her institution from Novartis, Pfizer, and Amgen. Dr. Ernste has received research support from Octapharma and Genentech (less than $10,000 each). No other disclosures relevant to this article were reported.
Access to the complete de-identified data can be made available following approval. Requests for additional study-related data can be sent to Paras Karmacharya at [email protected].

Abstract

Objective

To determine the incidence of psoriatic arthritis (PsA) in a US population and describe trends in incidence and mortality over 5 decades.

Methods

The previously identified population-based cohort that included Olmsted County, Minnesota residents ≥18 years of age who fulfilled PsA criteria during 1970–1999 was extended to include patients with incident PsA during 2000–2017. Age- and sex-specific incidence rates and point prevalence, adjusted to the 2010 US White population, were reported.

Results

There were 164 incident cases of PsA in 2000–2017 (mean ± SD age 46.4 ± 12.0 years; 47% female). The overall age- and sex-adjusted annual incidence of PsA per 100,000 population was 8.5 (95% confidence interval [95% CI] 7.2–9.8) and was higher in men (9.3 [95% CI 7.4–11.3]) than women (7.7 [95% CI 5.9–9.4]) in 2000–2017. Overall incidence was highest in the 40–59 years age group. The incidence rate was relatively stable during 2000–2017, with no evidence of an overall increase or an increase in men only (but a modest increase of 3% per year in women), compared to 1970–1999 when a 4%-per-year increase in incidence was observed. Point prevalence was 181.8 per 100,000 population (95% CI 156.5–207.1) in 2015. The percentage of women among those with PsA increased from 39% in 1970–1999 and 41% in 2000–2009 to 54% in 2010–2017 (P = 0.08). Overall survival in PsA did not differ from the general population (standardized mortality ratio 0.85 [95% CI 0.61–1.15]).

Conclusion

The incidence of PsA in this predominantly White US population was stable in 2000–2017, in contrast to previous years. However, an increasing proportion of women with PsA was found in this study.